Gefitinib

Small molecule

Also known as ZD1839

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
EU
  • Iressa: locally advanced or metastatic NSCLC with activating EGFR mutations
Product first approved 2009EMA
CA
  • IRESSA (gefitinib) is indicated for:  the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK (see 7 WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests). This indication was based on progression-free survival (PFS). After 78% of trial patients had died, no statistically significant difference in overall survival (OS) was demonstrated with first line IRESSA compared to the first line chemotherapy doublet in patients with EGFR mutation positive tumours...
Product first approved 2003Health Canada
JP
  • Iressa 250 mg: inoperable or recurrent non-small cell lung cancer (first approval worldwide)
Product first approved 2002investegate.co.uk

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Non-Small Cell Lung Cancer
NCT02411448 · Eli Lilly and Company
2015-05-06 – 2026-12 · Metastatic Non-Small Cell Lung Cancer
What this study did
NCT03203590 · Sun Yat-sen University
2017-09 – 2026-01 · 2-year Disease-Free Survival
What this study did
NCT04028778 · Sun Yat-sen University
2019-04-10 – 2022-12 · Lung Cancer, Nonsmall Cell
What this study did
NCT01951469 · Sun Yat-sen University
2016-01 – 2022-12 · Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation
What this study did
NCT01405079 · Guangdong Association of Clinical Trials
2011-09-19 – 2020-12 · Non-small Cell Lung Cancer
What this study did
NCT03656393 · Shenzhen People's Hospital
2018-08-31 – 2020-09-30 · NSCLC, EGFR
What this study did
NCT02518802 · Tang-Du Hospital
2015-01 – 2020-01 · Lung Neoplasms
What this study did
NCT01544179 · AstraZeneca
2012-03-15 – 2019-11-20 · Non-Small Cell Lung Cancer
What this study did
NCT02859077 · Shanghai Pulmonary Hospital, Shanghai, China
2016-08 – 2018-07 · Non-Small-Cell Lung Cancer
What this study did
NCT01404260 · Guangdong Association of Clinical Trials
2011-06 – 2015-10 · Non-small Cell Lung Cancer
What this study did
NCT00006049 · AstraZeneca
started 2000-05 · Lung Cancer
What this study did
NCT00006048 · AstraZeneca
started 2000-05 · Lung Cancer
What this study did
NCT00955695 · National Cancer Center, Korea
started 2009-05 · Lung Cancer
What this study did
NCT00049543 · National Cancer Institute (NCI)
2002-09 – 2011-04 · Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
What this study did
NCT00807066 · Fondazione Humanitas per la Ricerca
2008-11 – 2010-10 · Non Small Cell Lung Cancer
What this study did
NCT00455936 · National Cancer Center, Korea
2005-10 – 2010-03 · Lung Cancer
What this study did
NCT00478049 · AstraZeneca
2005-09 – 2009-02 · NSCLC
What this study did
NCT00091156 · European Organisation for Research and Treatment of Cancer - EORTC
2004-05 – 2008-07 · Lung Cancer
What this study did
NCT00076388 · AstraZeneca
2004-02 – 2007-10 · Non-Small-Cell Lung Carcinoma
What this study did
NCT00234468 · AstraZeneca
2004-01 – 2007-08 · Non Small Cell Lung Carcinoma
What this study did
NCT00252707 · AstraZeneca
2003-09 – 2006-11 · Non-Small Cell Lung Cancer
What this study did
NCT00144066 · West Japan Thoracic Oncology Group
started 2003-01 · Lung Cancer
What this study did
NCT00080340 · Telik
est. completion 2005-05 · Non Small Cell Lung Carcinoma
What this study did
NCT00242801 · AstraZeneca
2003-07 – 2005-04 · NSCLC
What this study did
Other / comorbidity
NCT02929693 · Shanghai University of Traditional Chinese Medicine
2016-10 – 2019-06 · Cancer
What this study did
NCT00357734 · AstraZeneca
2005-01 – 2015-05 · Lung Cancer, Breast Cancer
What this study did
NCT00088907 · National Cancer Institute (NCI)
2004-08 – 2012-08 · Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
What this study did
NCT01243398 · University of Oxford
2009-03 – 2012-05 · Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
What this study did
NCT00352079 · NCIC Clinical Trials Group
2007-01-04 – 2012-01-06 · Bladder Cancer
What this study did
NCT00206219 · AstraZeneca
2003-11 – 2007-09 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00635973 · AstraZeneca
2000-02 – 2003-10 · Cancer
What this study did
Phase 2/3 (6)
Non-Small Cell Lung Cancer
NCT02326285 · AIO-Studien-gGmbH
2015-11 – 2018-01 · Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB, Activating EGFR Mutation, NSCLC
What this study did
NCT02338011 · Shanghai Chest Hospital
2014-11 – 2017-11 · Non-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
What this study did
NCT00259064 · AstraZeneca
2004-09 – 2016-04 · NSCLC
What this study did
NCT01769066 · Fudan University
2009-12 – 2014-02 · NSCLC
What this study did
Other / comorbidity
NCT00234429 · AstraZeneca
2003-11 – 2006-06 · Colorectal Cancer
What this study did
Phase 2 (171)
Non-Small Cell Lung Cancer
NCT02347839 · Sun Yat-sen University
2016-01-01 – 2027-01-01 · Lung Cancer
What this study did
NCT02856893 · European Organisation for Research and Treatment of Cancer - EORTC
2017-10-10 – 2025-08-12 · NSCLC
What this study did
NCT03944772 · AstraZeneca
2019-06-25 – 2025-05-06 · Non-Small Cell Lung Cancer
What this study did
NCT03292133 · Massachusetts General Hospital
2017-10-31 – 2025-03-04 · Lung Cancer
What this study did
NCT04425187 · Fudan University
2020-06-08 – 2022-12-31 · PFS
What this study did
NCT04358562 · Second Affiliated Hospital of Nanchang University
2020-05-01 – 2022-11-01 · Non-small Cell Lung Cancer, EGFR Gene Mutation
What this study did
NCT03374280 · Guangzhou Medical University
2016-12-01 – 2021-12-30 · Non Small Cell Lung Cancer
What this study did
NCT03267654 · Qilu Pharmaceutical Co., Ltd.
2017-10-12 – 2021-12-30 · Non-small-cell Lung Cancer
What this study did
NCT03457337 · Henan Cancer Hospital
2018-03-28 – 2021-10-31 · Advanced NSCLC With EGFR Mutation
What this study did
NCT01610336 · Novartis Pharmaceuticals
2012-04-05 – 2020-05-27 · Non-small Cell Lung Cancer
What this study did
NCT03486496 · Fujian Cancer Hospital
2018-06-05 – 2020-02-01 · Lung Adenocarcinoma, EGFR Mutation
What this study did
NCT02951637 · Shanghai Chest Hospital
2016-12 – 2019-12 · Lung Adenocarcinoma
What this study did
NCT03123484 · China Medical University, China
2017-04 – 2019-10 · Non Small Cell Lung Cancer
What this study did
NCT02976116 · Hutchison Medipharma Limited
2016-12 – 2019-06-28 · NSCLC
What this study did
NCT03399669 · Samsung Medical Center
2015-02-17 – 2018-12-31 · Non-small Cell Lung Cancer
What this study did
NCT02930954 · Caicun Zhou
2016-11 – 2018-12 · Non-small-cell Lung Cancer
What this study did
NCT03002844 · Shanghai Pulmonary Hospital, Shanghai, China
2016-12 – 2018-12 · Nonsmall Cell Lung Cancer, EGFR Gene Mutation
What this study did
NCT01864681 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2013-05 – 2018-06-04 · NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC, Stage IV NSCLC
What this study did
NCT01933347 · Guangdong Association of Clinical Trials
2014-04-07 – 2018-04-10 · Non Small Cell Lung Cancer
What this study did
NCT02804776 · National Cancer Centre, Singapore
2015-01-27 – 2018-02-21 · Non-small Cell Lung Cancer
What this study did
NCT01749072 · Peking Union Medical College Hospital
2012-12 – 2017-12 · Non-small Cell Lung Cancer, Effects of Chemotherapy
What this study did
NCT01965275 · Anhui Medical University
2013-10 – 2017-12 · Self Efficacy, Drug Toxicity
What this study did
NCT01391260 · ZhuGuangYing
2011-07 – 2017-07 · Non-small Cell Lung Cancer
What this study did
NCT02025218 · Amsterdam UMC, location VUmc
2014-01 – 2017-06 · Lung Cancer
What this study did
NCT00986284 · Tianjin Medical University Cancer Institute and Hospital
2009-09 – 2016-11 · Non Small Cell Lung Cancer
What this study did
NCT01485809 · Seoul Veterans Hospital
2011-10 – 2016-11 · Squamous Cell Carcinoma of Bronchus
What this study did
NCT01955421 · Sun Yat-sen University
2013-07 – 2016-06 · Advanced Stage Non Small Cell Lung Cancer
What this study did
NCT01871480 · Kunming Medical University
2013-05 – 2016-05 · Non-Small Cell Lung Cancer
What this study did
NCT02319577 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2012-03 – 2015-12 · Non Small Cell Lung Cancer
What this study did
NCT01510990 · Asan Medical Center
2012-04 – 2015-11 · Non-small Cell Lung Cancer
What this study did
NCT01833572 · Fudan University
2013-05 – 2015-10 · Non-small-cell Lung Cancer
What this study did
NCT01502202 · National Cancer Center, Korea
2012-03 – 2015-02 · Non Small Cell Lung Cancer, Adenocarcinoma
What this study did
NCT01755923 · Peking Union Medical College Hospital
2012-12 – 2014-12 · Non-small Cell Lung Cancer
What this study did
NCT01530334 · AstraZeneca
2012-07 – 2014-07 · Lung Cancer
What this study did
NCT01498562 · Yonsei University
2011-12 – 2014-06 · Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT01783834 · Gachon University Gil Medical Center
2008-02 – 2014-06 · Previous Treated Metastatic Non-small Cell Lung Cancer
What this study did
NCT01017679 · Sun Yat-sen University
2009-05 – 2013-12 · Non-small Cell Lung Cancer
What this study did
NCT01024712 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
started 2009-05 · Lung Cancer
What this study did
NCT01196234 · Asan Medical Center
2009-12 – 2012-12 · Non Small Cell Lung Cancer
What this study did
NCT00411047 · Massachusetts General Hospital
2005-09 – 2012-12 · Lung Cancer
What this study did
NCT01312337 · Samsung Medical Center
2010-09 – 2012-08 · Nonsmall Cell Lung Cancer
What this study did
NCT00231465 · H. Lee Moffitt Cancer Center and Research Institute
2003-07 – 2012-08 · Non-Small Cell Lung Cancer
What this study did
NCT01192243 · Fudan University
2009-12 – 2011-12 · Toxicity, Non-small Cell Lung Cancer
What this study did
NCT00824746 · Chonnam National University Hospital
2009-01 – 2011-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00452244 · National Cancer Center, Korea
2006-05 – 2011-03 · Lung Cancer
What this study did
NCT00614809 · Guangdong Provincial People's Hospital
2007-12 – 2010-12 · Non-Small Cell Lung Cancer, Brain Metastasis
What this study did
NCT00616499 · Yonsei University
2006-11 – 2010-11 · Lung Cancer
What this study did
Phase 1/2 (30)
Non-Small Cell Lung Cancer
NCT03122717 · Dana-Farber Cancer Institute
2017-05-09 – 2027-10 · Non-Small Cell Lung Cancer
What this study did
NCT02039674 · Merck Sharp & Dohme LLC
2014-02-21 – 2021-10-18 · Non-small Cell Lung Carcinoma
What this study did
NCT01982955 · Merck KGaA, Darmstadt, Germany
2013-12-23 – 2021-10-14 · Non-small Cell Lung Cancer
What this study did
NCT03758287 · Sunshine Lake Pharma Co., Ltd.
2016-11 – 2021-09-17 · Non-small Cell Lung Cancer
What this study did
NCT00809237 · National University Hospital, Singapore
2008-11 – 2014-11 · Non-small Cell Lung Cancer
What this study did
NCT01027676 · National Cancer Center, Korea
2010-06 – 2014-03 · Non-Small-Cell Lung Carcinoma
What this study did
NCT01039948 · AVEO Pharmaceuticals, Inc.
2009-12 – 2013-08 · Carcinoma, Non-Small Cell-Lung, Lung Neoplasms, Lung Cancer, Respiratory Tract Neoplasms
What this study did
NCT00268255 · Barbara Ann Karmanos Cancer Institute
— · Non-small Cell Lung Cancer
What this study did
NCT00098462 · Jonsson Comprehensive Cancer Center
started 2004-10 · Lung Cancer
What this study did
NCT00096486 · Memorial Sloan Kettering Cancer Center
2004-05 – 2010-07 · Lung Cancer
What this study did
NCT00238628 · Stanford University
2004-04 – 2005-12 · Lung Cancer
What this study did
NCT00062270 · University of Alabama at Birmingham
2003-05 – 2004-09 · Lung Cancer
What this study did
Other / comorbidity
NCT00317772 · M.D. Anderson Cancer Center
2004-09-02 – 2020-11-04 · Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
What this study did
NCT00086957 · City of Hope Medical Center
2004-01 – 2015-08 · Breast Cancer
What this study did
NCT00352105 · David Adelstein
2006-04 – 2010-05 · Head and Neck Cancer
What this study did
NCT00042991 · National Cancer Institute (NCI)
2002-07 – 2010-03 · Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma
What this study did
NCT00212108 · National University Hospital, Singapore
2003-11 – 2009-01 · Nasopharyngeal Carcinoma
What this study did
NCT00113529 · Pfizer
2004-10 – 2008-10 · Carcinoma, Renal Cell
What this study did
NCT00085566 · Memorial Sloan Kettering Cancer Center
2004-03 – 2008-02 · Brain and Central Nervous System Tumors, Prostate Cancer
What this study did
NCT00423397 · University of California, San Diego
2006-09 – 2008-01 · Non-melanomatous Skin Cancer
What this study did
NCT00195078 · Weill Medical College of Cornell University
2004-04 – 2006-09 · Head and Neck Cancer
What this study did
NCT00239291 · AstraZeneca
2003-01 – 2006-05 · Non-Metastatic Prostate Cancer
What this study did
NCT00093652 · Roswell Park Cancer Institute
2003-05 – 2006-05 · Esophageal Cancer
What this study did
NCT00239304 · AstraZeneca
2003-06 – 2006-03 · Head and Neck Neoplasms
What this study did
NCT00242788 · AstraZeneca
2004-02 – 2005-11 · Colorectal Cancer
What this study did
NCT00087334 · Roswell Park Cancer Institute
2004-01 – 2005-11 · Colorectal Cancer
What this study did
NCT00052208 · National Cancer Institute (NCI)
2002-03 – 2005-06 · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
What this study did
NCT00234416 · AstraZeneca
2002-08 – 2005-03 · Pancreatic Cancer
What this study did
NCT00026299 · University of Chicago
2001-09 – 2005-02 · Colorectal Cancer
What this study did
NCT00237900 · AstraZeneca
2003-07 – 2004-02 · Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
What this study did
Phase 1 (38)
Non-Small Cell Lung Cancer
NCT07458919 · Fuzhou General Hospital
2026-03-30 – 2030-10-30 · Lung Cancer
What this study did
NCT03333343 · Novartis Pharmaceuticals
2018-01-29 – 2027-07-12 · EGFR-mutant Non-small Cell Lung Cancer
What this study did
NCT02088112 · MedImmune LLC
2014-03-24 – 2021-03-09 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04390984 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-26 – 2021-03 · NSCLC
What this study did
NCT03599518 · Daiichi Sankyo Co., Ltd.
2018-09-21 – 2020-06-29 · Non Small Cell Lung Cancer
What this study did
NCT03050411 · Peking University Third Hospital
2016-05 – 2019-10 · Nonsmall Cell Lung Cancer
What this study did
NCT02374645 · Hutchison Medipharma Limited
2015-04 – 2018-09-14 · Non-Small Cell Lung Cancer
What this study did
NCT02151721 · Kanazawa University
2014-06-01 – 2018-02-20 · Non-Small-Cell Lung Carcinoma
What this study did
NCT02321293 · Lady Davis Institute
2015-08 – 2016-12 · Lung Cancer
What this study did
NCT02040064 · Gustave Roussy, Cancer Campus, Grand Paris
2014-01 – 2016-03 · Non Small Cell Lung Cancer
What this study did
NCT00372515 · David M. Jackman, MD
2006-06 – 2015-04 · Non-Small Cell Lung Cancer
What this study did
NCT01602289 · Eli Lilly and Company
2012-06 – 2014-08 · Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung
What this study did
NCT00328562 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2003-12 – 2010-09 · Non-Small Cell Lung Carcinoma (NSCLC)
What this study did
NCT00310154 · Wake Forest University Health Sciences
2003-11 – 2010-08 · Lung Cancer
What this study did
NCT00497250 · Fudan University
2007-07 – 2009-10 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00820417 · Harrison Clinical Research
2004-06 – 2008-05 · Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT00255489 · AstraZeneca
2004-05 – 2006-06 · Non-small-cell Lung Cancer
What this study did
NCT00162318 · Eli Lilly and Company
2005-03 – 2006-04 · Non-Small-Cell Lung Carcinoma
What this study did
NCT00252798 · AstraZeneca
2002-07 – 2005-10 · Non Small Cell Lung Carcinoma
What this study did
NCT00005806 · Memorial Sloan Kettering Cancer Center
1999-09 – 2002-03 · Lung Cancer
What this study did
Other / comorbidity
NCT03050177 · Hunan Kelun Pharmaceutical Co., Ltd.
2016-09-01 – 2016-12-01 · Healthy
What this study did
NCT03050164 · Hunan Kelun Pharmaceutical Co., Ltd.
2016-09-08 – 2016-11-04 · Bioequivalence Study
What this study did
NCT00132158 · St. Jude Children's Research Hospital
2005-09 – 2011-10 · Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
What this study did
NCT00083057 · National Institutes of Health Clinical Center (CC)
2004-05 – 2010-11 · Head and Neck Cancer
What this study did
NCT00033449 · National Cancer Institute (NCI)
2002-02 – 2010-04 · Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
What this study did
NCT00186979 · St. Jude Children's Research Hospital
2003-05 – 2010-03 · Solid Tumors
What this study did
NCT00681967 · AstraZeneca
2004-02 – 2009-10 · Head and Neck Cancer
What this study did
NCT00290719 · University of California, San Francisco
2005-11 – 2008-06 · Esophageal Cancer
What this study did
NCT00127829 · AstraZeneca
2005-07 – 2008-01 · Tumors
What this study did
NCT00039390 · National Cancer Institute (NCI)
2002-04 – 2007-05 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00084708 · Roswell Park Cancer Institute
2002-11 – 2007-05 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00026364 · National Cancer Institute (NCI)
2001-11 – 2006-12 · Colorectal Cancer
What this study did
NCT00185835 · Stanford University
2002-06 – 2006-07 · Head and Neck Cancer, Carcinoma, Squamous Cell
What this study did
NCT00084786 · Memorial Sloan Kettering Cancer Center
2004-03 – 2006-07 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00502060 · AstraZeneca
2004-08 – 2006-06 · Advanced Tumor
What this study did
NCT00027625 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2002-01-28 – 2005-11-01 · Brain and Central Nervous System Tumors
What this study did
NCT00040781 · National Cancer Institute (NCI)
2002-06 – 2004-10 · Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
Phase 4 (8)
Non-Small Cell Lung Cancer
NCT03264794 · Jiangsu Famous Medical Technology Co., Ltd.
2017-08 – 2022-06 · Non-small Cell Lung Cancer
What this study did
NCT02031601 · Qilu Hospital of Shandong University
2014-01 – 2017-12 · Non-Small-Cell Lung Cancer
What this study did
NCT02299765 · Sichuan University
2014-12 – 2017-10 · Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation
What this study did
NCT01203917 · AstraZeneca
2010-09 – 2016-06 · Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
What this study did
NCT01000740 · AstraZeneca
2009-08 – 2010-04 · Non-small Cell Lung Cancer
What this study did
NCT00536107 · AstraZeneca
2007-10 – 2009-08 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00608868 · AstraZeneca
2007-01 – 2009-01 · Non Small Cell Lung Carcinoma
What this study did
Early phase / not applicable (13)
Non-Small Cell Lung Cancer
NCT03381430 · Qilu Pharmaceutical Co., Ltd.
2018-06 – 2025-12 · Lung Cancer
What this study did
NCT03766490 · The First Affiliated Hospital of Soochow University
2019-03-30 – 2020-12-20 · Non-Small-Cell Lung
What this study did
NCT03602027 · Second Affiliated Hospital of Nanchang University
2018-08-01 – 2019-02-01 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT02282267 · Peking University Cancer Hospital & Institute
2014-10 – 2018-02 · Lung Adenocarcinoma
What this study did
NCT02148380 · Baohui Han
2014-05 – 2015-12 · Non-Small-Cell Lung Cancer
What this study did
NCT03157310 · Qilu Hospital of Shandong University
2009-05-01 – 2015-07-12 · Overal Survival, Non-small Cell Lung Cancer
What this study did
NCT01776684 · Samsung Medical Center
2012-06 – 2015-05 · EGFR Mutation Positive Non-small Cell Lung Cancer
What this study did
NCT01363557 · Assistance Publique - Hôpitaux de Paris
2012-03 – 2013-05 · EGFR-mutated Lung Adenocarcinoma, Brain Metastasis
What this study did
NCT00104728 · H. Lee Moffitt Cancer Center and Research Institute
2004-10 – 2009-03 · Lung Cancer
What this study did
NCT00068497 · National Cancer Institute (NCI)
2003-08 – 2007-12 · Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Parathyroid Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Thyroid Cancer, Recurrent Verrucous Carcinoma of the Larynx, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Larynx, Stage IIIB Non-small Cell Lung Cancer, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Follicular Thyroid Cancer, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Papillary Thyroid Cancer, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Follicular Thyroid Cancer, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Papillary Thyroid Cancer, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Follicular Thyroid Cancer, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Papillary Thyroid Cancer, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Thryoid Gland Nonmedullary Carcinoma, Thyroid Gland Medullary Carcinoma, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
What this study did
Other / comorbidity
NCT04642547 · RenJi Hospital
2020-12-02 – 2023-03-31 · Hepatocellular Carcinoma, Molecular Targeted Therapy
What this study did
NCT02013089 · Sun Yat-sen University
2013-12 – 2017-12 · Gastrointestinal Cancers
What this study did
NCT00091247 · Alliance for Clinical Trials in Oncology
2004-12 – 2009-07 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
Used as active comparator (16)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (13)
Non-Small Cell Lung Cancer
NCT04143607 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
2019-07-23 – 2026-09-30 · Locally Advanced or Metastatic NSCLC
What this study did
NCT04248829 · Yuhan Corporation
2020-02-13 – 2026-04-22 · Non-Small Cell Lung Cancer
What this study did
NCT03787992 · Allist Pharmaceuticals, Inc.
2019-05-30 – 2026-03 · Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
What this study did
NCT03866499 · Beta Pharma Shanghai
2021-04-30 – 2025-12-30 · NSCLC
What this study did
NCT02296125 · AstraZeneca
2014-12-03 – 2025-11-20 · Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
What this study did
NCT03529084 · Novartis Pharmaceuticals
2018-07-24 – 2024-06-03 · Carcinoma, Non-small Cell Lung
What this study did
NCT03856697 · Hangzhou ACEA Pharmaceutical Research Co., Ltd.
2019-03 – 2024-03 · Advanced Non-small Cell Lung Cancer
What this study did
NCT04239833 · Nanjing Sanhome Pharmaceutical, Co., Ltd.
2020-01-31 – 2024-01-31 · Non-Small Cell Lung Cancer
What this study did
NCT03849768 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2019-02-01 – 2023-06-30 · Non Small Cell Lung Cancer
What this study did
NCT01774721 · Pfizer
2013-05-09 – 2022-01-27 · Non-small Cell Lung Cancer With EGFR-Activating Mutations
What this study did
NCT02588261 · Astellas Pharma Global Development, Inc.
2016-02-11 – 2017-12-21 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT01024413 · Chinese Society of Lung Cancer
2009-07 – 2015-06 · Thoracic Neoplasms
What this study did
NCT01040780 · Betta Pharmaceuticals Co., Ltd.
2009-02 – 2011-12 · Non-small Cell Lung Cancer
What this study did
Phase 2/3 (1)
Non-Small Cell Lung Cancer
NCT03653546 · Alpha Biopharma (Jiangsu) Co., Ltd.
2018-10-29 – 2022-07-12 · Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
What this study did
Phase 2 (2)
Non-Small Cell Lung Cancer
NCT01466660 · Boehringer Ingelheim
2011-12-13 – 2019-04-12 · Lung Neoplasms
What this study did
Other / comorbidity
NCT01556191 · Intergroupe Francophone de Cancerologie Thoracique
2012-05-15 – 2020-06-17 · Stage IV Lung Cancer
What this study did
Appears in other studies (17)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (7)
Non-Small Cell Lung Cancer
NCT02824458 · Sun Yat-sen University
2016-06 – 2023-12 · EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
What this study did
NCT02714010 · Sun Yat-sen University
2015-08 – 2022-12 · Non-Small Cell Lung Cancer
What this study did
NCT02893332 · Sichuan Provincial People's Hospital
2016-01-15 – 2020-08-30 · Stage IV EGFR Mutated Non-Small Cell Lung Cancer
What this study did
NCT01017874 · Eli Lilly and Company
2009-11 – 2014-10 · Non Small Cell Lung Cancer
What this study did
NCT01158170 · Zhejiang Cancer Hospital
2010-06 – 2013-12 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT02882984 · Sichuan Provincial People's Hospital
2015-03 – 2020-12 · Stage IV EGFR Mutated NSCL With Brain Metastases
What this study did
NCT02889692 · Shanghai University of Traditional Chinese Medicine
2013-03 – 2017-06-01 · Cancer
What this study did
Phase 2/3 (1)
Non-Small Cell Lung Cancer
NCT02387086 · Bai Jun
2015-05 – 2017-05 · NSCLC
What this study did
Phase 2 (6)
Non-Small Cell Lung Cancer
NCT03720873 · Fujian Cancer Hospital
2018-10 – 2022-09 · EGFR Gene Mutation
What this study did
NCT03389256 · Sichuan Cancer Hospital and Research Institute
2018-12-30 – 2022-08-30 · Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms, Non-Small-Cell Lung
What this study did
NCT02788058 · First People's Hospital of Hangzhou
2016-05 – 2022-05 · Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer
What this study did
NCT01469000 · Eli Lilly and Company
2012-02 – 2017-11 · Carcinoma, Non Small Cell Lung
What this study did
NCT01784549 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2012-07 – 2015-12 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT00135135 · St. Jude Children's Research Hospital
2005-08 – 2007-06 · Neuroblastoma
What this study did
Phase 1/2 (2)
Non-Small Cell Lung Cancer
NCT06071013 · China Medical University Hospital
2024-02-23 – 2026-08-27 · Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
What this study did
NCT01513174 · Spanish Lung Cancer Group
2011-08 – 2016-07 · Non Small Cell Lung Cancer
What this study did
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT07271446 · Precision Biotech Taiwan Corp.
2018-09-01 – 2023-12-01 · Non-small Cell Lung Cancer
What this study did

Competitive landscape

This mechanism is crowded: 41 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gefitinib: this drugApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
Cetuximab
Approved(overall)
Monoclonal antibodyEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
AsandeutertinibPhase 3Small moleculeEGFRWeak signal
NCT05146219: Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
BefotertinibPhase 3Small moleculeEGFRPartial signal
NCT04206072: Median IRC-assessed PFS: 22.1 months (befotertinib) vs 13.8 months (icotinib); HR 0.49 (95% CI 0.36-0.68), P<0.0001
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
FHND9041Phase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
FurmonertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
IcotinibPhase 3Small moleculeEGFRPartial signal
NCT01719536: Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006
NCT01040780: Progression Free Survival (2-7 months): Icotinib 4.6 months (95% CI 3.5 to 6.3) vs Gefitinib 3.4 months (95% CI 2.3 to 3.8)
LimertinibPhase 3Small moleculeEGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR)Reliable signal
NCT04143607: NCT04143607 (limertinib/ASK120067 vs gefitinib first-line trial), primary endpoint median PFS: limertinib 20.7 months vs gefitinib 9.7 months; HR 0.44
PruvonertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
RezivertinibPhase 3Small moleculeEGFRReliable signal
NCT03866499: REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001
NCT03812809: ORR by blinded independent central review 64.6% (95% CI 58.0%-70.8%)
Rilertinib (SH-1028)Phase 3Small moleculeEGFRReliable signal
NCT04239833: Median PFS: 19.3 months (rilertinib/SH-1028) vs 9.8 months (gefitinib), HR 0.46, P<0.0001 -- primary endpoint met.
ZipalertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
PimurutamabPhase 2/3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
ZorifertinibPhase 2/3Small moleculeEGFRPartial signal
NCT03653546: Median PFS by blinded independent central review: 9.6 months (zorifertinib/AZD3759) vs 6.9 months (control, gefitinib or erlotinib); HR 0.719 (95% CI 0.580-0.893), p=0.0024
BEBT-109Phase 2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
JS111Phase 2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
SutetinibPhase 2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ANS02Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BBT-207Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BH-30643Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BPI-361175Phase 1/2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
Dositinib MesylatePhase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
DZD6008Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
H002Phase 1/2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
JIN-A02Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
PH009-1Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
SilevertinibPhase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
STX-241Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
VRN110755Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ALX2004Phase 1Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
AST2303Phase 1Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
EPI-326Phase 1Multispecific antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
HLX42Phase 1Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
HSK40118Phase 1Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 101 furthest-along competitors are listed; 510 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gefitinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2026-11 · NCT07829926 · CT.gov ↗
What to watch
2027 (2)
July 2027 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-12 · NCT03333343 · CT.gov ↗
What to watch
Phase 2Advanced Solid Tumors Which Are cMET-dependentActive not recruiting
Est. primary completion 2027-07-30 · NCT03040973 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 2Osteosarcoma, MetastasisRecruiting
Est. primary completion 2028-03 · NCT07477457 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-10-30 · NCT07458919 · CT.gov ↗
What to watch

See the full readout calendar ↗